Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237196 · ClinicalTrials.gov registry record · Phase 1
Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT02237196 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 121 participants.
The verdict
NCT02237196, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This trial will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP \[thymic stromal lymphopoietin\] antibody being co-developed by Amgen and MedImmune) can lead to lasting tolerance to cat allergen.The objective of the study is to determine whether one year of immunotherapy combined with MEDI9929/AMG 157 can induce tolerance to cat allergen.
Interventions
- BIOLOGICAL AMG 157
- BIOLOGICAL Cat Immunotherapy
- BIOLOGICAL Cat Immunotherapy Placebo
- BIOLOGICAL AMG 157 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2019-03-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237196
The ClinicalTrials.gov registry entry for NCT02237196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AMG 157 is the first listed.
NCT02237196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237196 about?
NCT02237196 is a clinical study titled "Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy". This trial will test whether a novel therapeutic approach, cat immunotherapy combined with an investigational new drug called MEDI9929/AMG 157 (an anti-TSLP \[thymic stromal lymphopoietin\] antibody being co-developed by Amgen and MedImmune) can lead to lasting tolerance to cat allergen.The objectiv...
What is the current status of trial NCT02237196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2015-03-03. Estimated completion is 2019-03-04.
What interventions are being tested in trial NCT02237196?
The interventions under investigation include: AMG 157 (BIOLOGICAL), Cat Immunotherapy (BIOLOGICAL), Cat Immunotherapy Placebo (BIOLOGICAL), AMG 157 Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02237196?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.